Viome Dx
Share
Decoding human biology to prevent, treat, and cure chronic disease, cancer, and aging.
In 2016 we founded Viome with a mission to make illness optional and bring our cutting-edge science and technology directly to individuals with advanced at-home testing. This includes returning the benefits of our discoveries to our users and being able to expand our testing capabilities even further.
We are happy to announce that the revolutionary mRNA technology and AI-powered platform behind our Intelligence™ Tests for precise food recommendations and supplements have paved the way for our line of Discovery™ Tests, which includes a series of diagnostic tests in development!
Today, we celebrate the launch of CancerDetect™ for Oral & Throat Cancer.
This test is the first to detect biomarkers for early-stage oral and throat cancers based on technology that has received FDA Breakthrough Device Designation. CancerDetect™ brings unprecedented accuracy to early cancer detection and prevention as the only oral and throat cancer test to offer detection with 95% specificity and 90% sensitivity.
CancerDetect™ is available to individuals at higher risk of developing these cancers, fulfilling an unmet need for advanced, earlier detection when it is most easy to treat. If detected early, these cancers can be treated and likely increase 5-year survival to 84% (compared to less than 50% without).
In addition to head and neck cancers, Viome has an extensive ongoing clinical study pipeline in gastrointestinal cancers, including colorectal cancer, pancreatic, ovarian, cervical, and biliary cancers. We currently have cancer research trials that use saliva, blood, stool, and tumor biopsies to understand the onset and progression of cancer. By identifying the biomarkers that lead to the development of cancers, Viome can optimize early detection and identify the right therapeutic targets.
Thank you to everyone at Viome that made this possible and our external academic partners!
https://lnkd.in/gdY7vaKR
01/07/2022
Meet Guruduth Banavar, Chief Technology Officer & Head of AI Discovery!
Guru is driven to develop and apply deep science and technology innovations to solve the big challenges of humanity, especially in health and education. He founded many successful initiatives, and is best known for his work on Host/Microbe Molecular Data Analysis, IBM Watson AI Systems, Smarter Cities, Services Innovation, Mobile Computing, and Distributed Systems.
Guru is the founding CTO of Viome Inc, where he leads AI and co-leads clinical research. Guru’s focus is on analyzing large host-microbiome gene expression datasets, discovering biomarkers, and identifying therapeutic targets from clinical research studies targeting metabolic, gastrointestinal, autoimmune, and neurological disorders, as well as cancer. He led the development of a first-of-a-kind saliva-based early detection system for oral and throat cancers using host/microbiome gene expression for Viome, which has received FDA’s designation as a breakthrough device.
"The oral cancer diagnostic is a first-of-a-kind proof of concept that showcases the power of the ViOS platform, and establishes a repeatable method for rapidly developing and validating novel diagnostics and therapeutics. We are happy to make this cutting edge platform available to the scientific community." - Guru Banavar
12/15/2021
We officially opened our state-of-the-art clinical laboratory in Bothell, WA!
Our lab is the only lab that uses clinically validated, direct-to-consumer, metatranscriptomic (unbiased RNA sequencing) analysis of stool, blood, and (soon) saliva samples. The labs support our clinical research activities and analyze customer samples that arrive from 93+ countries!
Our entire discovery platform (Viomega) is open access, and available to any clinician or researcher. Applications for accessing Viomega can be submitted here:
https://buff.ly/30lCsie
Click here to claim your Sponsored Listing.
Category
Address
11724 NE 195th Street Suite 101
Bothell, WA
98011
